ClinicalTrials.gg
CompletedNCT00439517FUTUREUpdated Jun 27, 2014Results posted

Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.

A Phase 2 interventional study of UFOX + Cetuximab and FOLFOX4 + Cetuximab in Previously Untreated Metastatic Colorectal Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 57 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-27.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is an exploratory study to compare activity and safety in 400 patients with previously untreated metastatic carcinoma of the colon treated with UFOX (a combination regimen of UFT® (Tegafur plus Uracil), Oxaliplatin, Folinic Acid) plus Cetuximab or FOLFOX-4 (a combination regimen of 5 Fluorouracil (5-FU), Oxaliplatin and Folinic Acid) plus Cetuximab)

02

Conditions studied

  • Previously Untreated Metastatic Colorectal Cancer

Keywords

  • Cancer
  • Colorectal
  • Metastatic
  • Untreated
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

This study's enrollment of 302 is above the median of 60 across 7,714 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed written
  • Inpatient or outpatient ≥ 18 years of age
  • Diagnosis of confirmed adenocarcinoma of the colon or rectum
  • First occurrence of disease (not curatively resectable)
  • Presence of at least one lesion measurable uni dimensionally by computerised tomography (CT) scan or magnetic resonance imaging (MRI). (Target lesion(s) must not lie within an irradiated area)
  • of ≥ 3 months
  • performance status of ≥ 60, at study entry
  • White blood cell count (WBC) ≥ 3 x 10\^9/L, with neutrophils ≥ 1.5 x 10\^9/L, ≥ 100 x 10\^9/L, and ≥ 9 g/dL
  • and alanine transaminase ≤ 2.5 x (ULN) (≤ 5 x ULN if liver metastasis are present)
  • Normal serum creatinine (in case of elevated creatinine, labelled ethylenediaminetetraacetic acid clearance ≥ 65 mL/min is acceptable)
  • Effective for both male and female subjects if the risk of conception exists
  • Tumor or archived sample available

Exclusion criteria

Exclusion criteria:

  • and/or (known or suspected)
  • Previous chemotherapy for colorectal cancer except treatment with progression of disease documented > 6 months after end of adjuvant treatment.
  • Previous oxaliplatin-based chemotherapy
  • Surgery (excluding diagnostic ) or irradiation within 4 weeks prior to randomization
  • Concurrent or previous chronic systemic immune therapy, targeted therapy, anti-vascular epithelial growth factor (VEGF) therapy, epidermal growth factor receptor (EGFR) pathway targeting therapy not indicated in the study protocol
  • Concurrent hormonal therapy not indicated in the study protocol except for physiologic replacement or
  • coronary artery disease, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia
  • Peripheral neuropathy >grade 1
  • Known reaction to any of the components of the treatment.
  • Any concurrent other than basal cell cancer of the skin, or pre-invasive cancer of the cervix. (Subjects with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the study)
  • Pregnancy (absence to be confirmed by ß-human chorionic gonadotrophin test) or lactation period
  • Known drug abuse/alcohol abuse
  • Legal incapacity or limited legal capacity
  • Medical or psychological condition which in the opinion of the investigator would not permit the subject to complete the study or sign meaningful
  • Participation in another clinical study within the 30 days before randomization
  • Significant disease which, in the investigator's opinion, would exclude the subject from the study
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    1

    UFOX + Cetuximab

    Drug: UFOX + Cetuximab

  • Active comparator
    2

    FOLFOX4 + Cetuximab

    Drug: FOLFOX4 + Cetuximab

Interventions

  • DrugUFOX + Cetuximab

    Drug page: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22) * Oxaliplatin infusion (85mg/m\^2) on days 1 and 15 (every 2 weeks) * Oral UFT® (250mg/m\^2 tegafur + 560 mg/m\^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21 * Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21

  • DrugFOLFOX4 + Cetuximab

    Drug page: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    * Cetuximab infusion (400 mg/m\^2 on day 1 of cycle 1 and 250 mg/m\^2 at each subsequent day 1, as well as on days 8, 15 and 22) * Oxaliplatin infusion (85 mg/m\^2) on days 1 and 15 (every 2 weeks) * 5-FU bolus + infusions (400 mg/m\^2) on days 1, 2, 15 and 16 * Folinic Acid infusions (200 mg/m\^2) on days 1, 2, 15 and 16

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria

    Time frame: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Secondary outcomes

  1. Best Overall Response (BOR)

    BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as "Disappearance of all target lesions plus disappearance of all non-target lesions \& without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as "At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later

    Time frame: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

  2. Overall Survival (OS)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

  3. Overall Survival (OS)

    Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

    Time frame: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011

  4. Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)

    All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0="Not at all" to 4="Very much". For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL.

    Time frame: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays

  5. QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire

    The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL.

    Time frame: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

  6. QOL Therapy Preference Questionnaire (TPQ)

    TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic.

    Time frame: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

  7. Treatment Impact on Social Daily Living and Health Care Resource Utilization

    Non-protocol medical care visits and consultations

    Time frame: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009

  8. Safety - Number of Patients Experiencing Any Adverse Event

    Please refer to Adverse Events section for details of individual serious adverse events and other adverse events

    Time frame: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

07

Results

Posted Jun 14, 2011
Limitations and caveats
Dosing of UFT/ folinic acid in the experimental arm were not directly recorded, so dosing data is not fully available in the UFOX plus cetuximab arm (36/151). Comparative conclusions on drug exposure might be impacted by a bias due to missing data.

Participant flow

First subject randomised 12 February 2007, last subject randomised 30 June 2008. Cut off date was 30th June 2009

Participant flow — Overall Study
MilestoneUFOX + CetuximabFOLFOX4 + Cetuximab
Started152150
Completed150150
Not completed20
Withdrew: Subject on treatment10
Withdrew: Subject in survival follow-up10

Outcome measures

PrimaryProgression-free Survival (PFS)

Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria

Time frame:
Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Reported as:
Median · months
Progression-free Survival (PFS)
monthsUFOX + CetuximabFOLFOX4 + Cetuximab
Progression-free Survival (PFS)6.6 (5.6 to 7.2)8.2 (7.5 to 9.2)
Statistical analysis
  • UFOX + Cetuximab vs FOLFOX4 + Cetuximab · Stratified log rank · p = 0.0048 · Hazard ratio (hr): 0.677 · 95% CI 0.515 to 0.889Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryBest Overall Response (BOR)

BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as "Disappearance of all target lesions plus disappearance of all non-target lesions \& without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as "At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later

Time frame:
Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Reported as:
Number · percentage of participants
Best Overall Response (BOR)
percentage of participantsUFOX + CetuximabFOLFOX4 + Cetuximab
Best Overall Response (BOR)37.5 (29.8 to 45.7)51.3 (43.0 to 59.6)
Statistical analysis
  • UFOX + Cetuximab vs FOLFOX4 + Cetuximab · Cochran-Mantel-Haenszel · p = 0.016 · Odds ratio (or): 1.756 · 95% CI 1.110 to 2.777Stratified odds ratio and Cochran-Mantel- Haenszel (CMH) statistics were calculated considering the randomization strata.
SecondaryOverall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Reported as:
Median · months
Overall Survival (OS)
monthsUFOX + CetuximabFOLFOX4 + Cetuximab
Overall Survival (OS)12.9 (11.5 to 15.8)15.5 (12.6 to 18.1)
Statistical analysis
  • UFOX + Cetuximab vs FOLFOX4 + Cetuximab · Stratified log rank · p = 0.3797 · Hazard ratio (hr): 0.855 · 95% CI 0.603 to 1.213Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryOverall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.

Time frame:
Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011
Reported as:
Median · months
Overall Survival (OS)
monthsUFOX + CetuximabFOLFOX4 + Cetuximab
Overall Survival (OS)16.8 (13.9 to 18.5)18.4 (15.3 to 20.9)
Statistical analysis
  • UFOX + Cetuximab vs FOLFOX4 + Cetuximab · Stratified log rank · p = 0.8575 · Hazard ratio (hr): 0.977 · 95% CI 0.755 to 1.263Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.
SecondaryQuality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)

All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0="Not at all" to 4="Very much". For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL.

Time frame:
At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays
Reported as:
Least squares mean · scores on a scale
Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)
scores on a scaleUFOX + CetuximabFOLFOX4 + Cetuximab
Baseline98.22 ± 1.72596.45 ± 1.749
Cycle 395.41 ± 1.73595.89 ± 1.806
Cycle 694.75 ± 2.09094.70 ± 2.126
SecondaryQOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire

The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL.

Time frame:
at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
Reported as:
Least squares mean · scores on a scale
QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire
scores on a scaleUFOX + CetuximabFOLFOX4 + Cetuximab
Baseline0.747 ± 0.0210.734 ± 0.021
Cycle 30.782 ± 0.0210.758 ± 0.022
Cycle 60.758 ± 0.0260.771 ± 0.026
SecondaryQOL Therapy Preference Questionnaire (TPQ)

TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic.

Time frame:
at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays
Reported as:
Number · percentage of participants
QOL Therapy Preference Questionnaire (TPQ)
percentage of participantsUFOX + CetuximabFOLFOX4 + Cetuximab
Baseline: Does not increase your risk of infection1816
Baseline: Does not interfere with daily activities1715
Baseline: Does not make you vomit414
Baseline: Does not give you diarrhea95
Cycle 3: Does not increase your risk of infection1515
Cycle 3: Does not interfere with daily activities1011
Cycle 3: Does not make you vomit410
Cycle 3: Does not give you diarrhea154
SecondaryTreatment Impact on Social Daily Living and Health Care Resource Utilization

Non-protocol medical care visits and consultations

Time frame:
From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009
Reported as:
Number · visits or consultations
Treatment Impact on Social Daily Living and Health Care Resource Utilization
visits or consultationsUFOX + CetuximabFOLFOX4 + Cetuximab
Emergency room visit3426
Hospital oupatient clinic visit4035
Practice visit71159
Home visit15130
General Practitioner consultation65124
Specialist consultation6284
Nurse consultation15123
Other consultation1918
SecondarySafety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for details of individual serious adverse events and other adverse events

Time frame:
Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009
Reported as:
Number · participants
Safety - Number of Patients Experiencing Any Adverse Event
participantsUFOX + CetuximabFOLFOX4 + Cetuximab
Safety - Number of Patients Experiencing Any Adverse Event151149

Adverse events

Collected over Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Dec 2006, until cut off date, 30 Jun 2009. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UFOX + Cetuximab—52/151 (34.4%)151/151 (100%)
FOLFOX4 + Cetuximab—48/150 (32%)146/150 (97.3%)
Most frequent serious events
Showing 10 of 85
Most frequent serious events
EventUFOX + CetuximabFOLFOX4 + Cetuximab
DiarrhoeaGastrointestinal disorders13/1514/150
VomitingGastrointestinal disorders9/1513/150
PyrexiaGeneral disorders3/1518/150
Central line infectionInfections and infestations1/1515/150
Abdominal painGastrointestinal disorders5/1514/150
IleusGastrointestinal disorders5/1512/150
Intestinal obstructionGastrointestinal disorders5/1512/150
General physical health deteriorationGeneral disorders0/1514/150
NauseaGastrointestinal disorders4/1510/150
Febrile neutropeniaBlood and lymphatic system disorders0/1512/150
Most frequent other events
Showing 10 of 59
Most frequent other events
EventUFOX + CetuximabFOLFOX4 + Cetuximab
DiarrhoeaGastrointestinal disorders79/15172/150
NauseaGastrointestinal disorders67/15155/150
NeutropeniaBlood and lymphatic system disorders10/15165/150
RashSkin and subcutaneous tissue disorders63/15147/150
Dermatitis acneiformSkin and subcutaneous tissue disorders40/15145/150
ParaesthesiaNervous system disorders38/15143/150
VomitingGastrointestinal disorders40/15132/150
AnorexiaMetabolism and nutrition disorders40/15136/150
FatigueGeneral disorders38/15138/150
ThrombocytopeniaBlood and lymphatic system disorders33/15137/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)UFOX + CetuximabFOLFOX4 + CetuximabTotal
Mean60.1 ± 10.0161 ± 11.0460.5 ± 10.53
Age, Customized
Age, Customized(participants)UFOX + CetuximabFOLFOX4 + CetuximabTotal
<65 years9384177
>=65 years5766123
Missing202
Sex: Female, Male
Sex: Female, Male(Participants)UFOX + CetuximabFOLFOX4 + CetuximabTotal
Female5755112
Male9595190
Region of Enrollment
Region of Enrollment(participants)UFOX + CetuximabFOLFOX4 + CetuximabTotal
Hong Kong7411
Greece9514
Thailand7916
Austria13922
Italy283361
France6814
Mexico404
Argentina5611
Brazil5914
Poland302757
Belgium5712
Australia6511
Germany272855
08

Study locations

57 sites
  • Research Site
    Buenos Aires, Argentina
  • Research Site
    Ciudad Autónoma Buenos Aires, Argentina
  • Research Site
    Perth, Australia
  • Research Site
    Wollongong, Australia
  • Research Site
    Graz, Austria
  • Research Site
    Wien, Austria
  • Research Site
    Leuven, Belgium
  • Research Site
    Liège, Belgium
  • Research Site
    Belo Horizonte, Brazil
  • Research site
    Cep Sao Paulo-SP, Brazil
  • Research Site
    Fortaleza, Brazil
  • Research Site
    Besancon Cedex, France
  • Research Site
    Caen-Cedex 5, France
  • Research Site
    La Roche sur Yon, France
  • Research Site
    Lille, France
  • Research Site
    Marseille, France
  • Research Site
    Nice, France
  • Research Site
    Saint-Herblain, France
  • Research Site
    Strasbourg, France
  • Research Site
    Berlin, Germany
  • Research Site
    Dortmund, Germany
  • Research Site
    Dresden, Germany
  • Research Site
    Frankfurt / Main, Germany
  • Research Site
    Hamburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Heidelberg, Germany
  • Research Site
    Kassel, Germany
  • Research Site
    Krefeld, Germany
  • Research Site
    Magdeburg, Germany
  • Research Site
    München, Germany
  • Research Site
    Oldenburg, Germany
  • Research Site
    Wiesbaden, Germany
  • Research Site
    Dragana, Greece
  • Research Site
    Thessaloniki, Greece
  • Research Site
    Voutes, Greece
  • Research Site
    Hong Kong, Hong Kong
  • Research Site
    Sha Tin, Hong Kong
  • Research Site
    Haifa, Israel
  • Research Site
    Jerusalem, Israel
  • Research Site
    Benevento, Italy
  • Research Site
    Brescia, Italy
  • Research Site
    Cremona, Italy
  • Research Site
    Forli, Italy
  • Research Site
    Padova, Italy
  • Research Site
    Pavia, Italy
  • Research Site
    Potenza, Italy
  • Research Site
    Reggio Emilia, Italy
  • Research Site
    Rimini, Italy
  • Research Site
    Roma, Italy
  • Research Site
    Sassari, Italy
  • Research Site
    Mexico-City, Mexico
  • Research Site
    Krakow, Poland
  • Research Site
    Lublin, Poland
  • Research Site
    Opole, Poland
  • Research Site
    Warsaw, Poland
  • Research Site
    Bangkok, Thailand
  • Research Site
    Pathumwan, Thailand
09

References and documents

Publications

  • Douillard JY, Zemelka T, Fountzilas G, Barone C, Schlichting M, Heighway J, Eggleton SP, Srimuninnimit V. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. Clin Colorectal Cancer. 2014 Mar;13(1):14-26.e1. doi: 10.1016/j.clcc.2013.11.009. Epub 2013 Nov 16. PubMed 24370353 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2007, a primary completion of Jun 2009 and a completion of May 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2007
First posted
Feb 23, 2007
Start
Feb 2007
Primary completionActual
Jun 2009
CompletionActual
May 2012
Results first posted
Jun 14, 2011
Last update
Jun 27, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 27, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00439517
Responsible party
Sponsor
First posted
Feb 23, 2007
Start date
Feb 2007
Primary completion
Jun 2009
Completion
May 2012
Results posted
Jun 14, 2011
Last update
Jun 27, 2014

Study contacts

Jean-Yves Douillard, MD PhD
principal investigator · Centre R Gauducheau

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetuximab

Start the discussion